DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

@article{Scheen2012DPP4II,
  title={DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.},
  author={A. J. Scheen},
  journal={Diabetes & metabolism},
  year={2012},
  volume={38 2},
  pages={89-101}
}
Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes. Direct comparisons with active glucose-lowering comparators in drug-naive patients have demonstrated that DPP-4 inhibitors exert slightly less pronounced HbA(1c) reduction than metformin (with the advantage of better gastrointestinal tolerability) and similar glucose-lowering effects as with a thiazolidinedione (TZD; with the advantage of no weight gain). In metformin-treated patients, gliptins… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 107 references

Similar Papers

Loading similar papers…